Qulipta and Ubrelvy Comparison

Qulipta®(atogepant)	Ubrelvy®(ubrogepant)
Prescription Only Qulipta is a prescription medication that is used as a preventative treatment for episodic migraines. It is a tablet that is taken once daily. The most common side effects are...	Prescription Only Ubrelvy is a medication that adults can use to treat acute migraine attacks. It works by blocking CGRP, a protein believed to contribute to migraine attacks by causing pain, blood...
Administration
Oral. Learn more.	Oral. Learn more.
Dosing
10 mg, 30 mg, or 60 mg once daily. Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.. Learn more.	50 mg or 100 mg as needed. Maximum daily dose: 200 mg. Severe Hepatic or Severe Renal Impairment: 50 mg.. Learn more.
Latin Shorthand
10mg qd, 30mg qd or 60mg qd Renal Impairment: 10mg qd. Learn more.	50 mg PRN or 100 mg PRN. Severe Renal Impairment: 50mg.. Learn more.
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	$0. Learn more.
Annual Cap
$6000. Learn more.	Maximum savings of $50 per pill for up to 13 prescription fills.. Learn more.
Assistance Expiration
12 30-day prescription fills. Learn more.	13 prescription fills. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.. Learn more.	The most common adverse reactions (at least 2% and greater than placebo) were nausea and somnolence.. Learn more.
Mechanism of Actions (MoA)
CGRP Antagonists. Learn more.	CGRP Antagonist. Learn more.
Special Populations
Is QULIPTA safe to use during pregnancy? There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically. Women who are pregnant or planning to become pregnant should consult with their healthcare provider to determine the best treatment option for their migraine. Is QULIPTA safe to use during lactation? There are no data on the presence of atogepant in human milk, the effects of atogepant on the breastfed infant, or the effects of atogepant on milk production. In lactating rats, oral dosing with atogepant resulted in levels of atogepant in milk approximately 2-fold higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition. Is QULIPTA safe to use in pediatric patients? Safety and effectiveness in pediatric patients have not been established. QULIPTA is not recommended for use in pediatric patients. Is QULIPTA safe to use in elderly patients? Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Is QULIPTA safe to use in patients with hepatic impairment? No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment. Is QULIPTA safe to use in patients with renal impairment? The renal route of elimination plays a minor role in the clearance of atogepant. No dose adjustment is recommended for patients with mild or moderate renal impairment.	Is it safe to take UBRELVY during pregnancy? There are no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women. Patients should be encouraged to enroll in the pregnancy exposure registry that monitors outcomes in women who become pregnant while taking UBRELVY by calling 1-833-277-0206 or visiting http://empresspregnancyregistry.com. What is the risk of birth defects or miscarriage when taking UBRELVY during pregnancy? In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated rate of major birth defects (2.2% -2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available. What are the clinical considerations when taking UBRELVY during pregnancy? Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy. What does animal data suggest about the use of UBRELVY during pregnancy? In animal studies, adverse effects on embryofetal development were observed following administration of ubrogepant during pregnancy or during pregnancy and lactation at doses greater than those used clinically and which were associated with maternal toxicity. No adverse effects on embryofetal development were observed when ubrogepant was administered to pregnant rats during the period of organogenesis. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available. What is the risk of taking UBRELVY while breastfeeding? There are no data on the presence of ubrogepant in human milk, the effects of ubrogepant on the breastfed infant, or the effects of ubrogepant on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for UBRELVY and any potential adverse effects on the breastfed infant from UBRELVY or from the underlying maternal condition. Is it safe to use UBRELVY in pediatric patients? Safety and effectiveness in pediatric patients have not been established. Are there any pharmacokinetic differences between elderly and younger patients when taking UBRELVY? Pharmacokinetic studies have shown no clinically significant differences between elderly and younger patients when taking UBRELVY. Was the use of UBRELVY studied in elderly patients? Clinical studies of UBRELVY did not include enough elderly patients to determine if they respond differently from younger patients. Dose selection for elderly patients should be cautious and typically start at the low end of the dosing range. How does hepatic impairment affect the exposure to UBRELVY? In patients with mild, moderate, or severe hepatic impairment, exposure to UBRELVY was increased by 7%, 50%, and 115%, respectively. No dose adjustment is necessary for mild or moderate hepatic impairment. However, for patients with severe hepatic impairment, dose adjustment is recommended. How does renal impairment affect the use of UBRELVY? Renal impairment has a minor effect on the clearance of UBRELVY. No dose adjustment is needed for patients with mild or moderate renal impairment. For those with severe renal impairment (CLcr 15-29 mL/min), dose adjustment is necessary. Patients with end-stage renal disease (CLcr <15 mL/min) should avoid the use of UBRELVY.

Qulipta®(atogepant)

Ubrelvy®(ubrogepant)

Prescription Only

Qulipta is a prescription medication that is used as a preventative treatment for episodic migraines. It is a tablet that is taken once daily. The most common side effects are...

Prescription Only

Ubrelvy is a medication that adults can use to treat acute migraine attacks. It works by blocking CGRP, a protein believed to contribute to migraine attacks by causing pain, blood...

Dosage & Administration

Administration

Oral. Learn more.

Dosing

10 mg, 30 mg, or 60 mg once daily. Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.. Learn more.

50 mg or 100 mg as needed. Maximum daily dose: 200 mg. Severe Hepatic or Severe Renal Impairment: 50 mg.. Learn more.

Latin Shorthand

10mg qd, 30mg qd or 60mg qd Renal Impairment: 10mg qd. Learn more.

50 mg PRN or 100 mg PRN. Severe Renal Impairment: 50mg.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$0. Learn more.

Annual Cap

$6000. Learn more.

Maximum savings of $50 per pill for up to 13 prescription fills.. Learn more.

Assistance Expiration

12 30-day prescription fills. Learn more.

13 prescription fills. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.. Learn more.

The most common adverse reactions (at least 2% and greater than placebo) were nausea and somnolence.. Learn more.

Mechanism of Actions (MoA)

CGRP Antagonists. Learn more.

CGRP Antagonist. Learn more.

Special Populations

Is QULIPTA safe to use during pregnancy?

There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically. Women who are pregnant or planning to become pregnant should consult with their healthcare provider to determine the best treatment option for their migraine.

Is QULIPTA safe to use during lactation?

There are no data on the presence of atogepant in human milk, the effects of atogepant on the breastfed infant, or the effects of atogepant on milk production. In lactating rats, oral dosing with atogepant resulted in levels of atogepant in milk approximately 2-fold higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition.

Is QULIPTA safe to use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established. QULIPTA is not recommended for use in pediatric patients.

Is QULIPTA safe to use in elderly patients?

Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Is QULIPTA safe to use in patients with hepatic impairment?

No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment.

Is QULIPTA safe to use in patients with renal impairment?

The renal route of elimination plays a minor role in the clearance of atogepant. No dose adjustment is recommended for patients with mild or moderate renal impairment.

Is it safe to take UBRELVY during pregnancy?

There are no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women. Patients should be encouraged to enroll in the pregnancy exposure registry that monitors outcomes in women who become pregnant while taking UBRELVY by calling 1-833-277-0206 or visiting http://empresspregnancyregistry.com.

What is the risk of birth defects or miscarriage when taking UBRELVY during pregnancy?

In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated rate of major birth defects (2.2% -2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available.

What are the clinical considerations when taking UBRELVY during pregnancy?

Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.

What does animal data suggest about the use of UBRELVY during pregnancy?

In animal studies, adverse effects on embryofetal development were observed following administration of ubrogepant during pregnancy or during pregnancy and lactation at doses greater than those used clinically and which were associated with maternal toxicity. No adverse effects on embryofetal development were observed when ubrogepant was administered to pregnant rats during the period of organogenesis. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available.

What is the risk of taking UBRELVY while breastfeeding?

There are no data on the presence of ubrogepant in human milk, the effects of ubrogepant on the breastfed infant, or the effects of ubrogepant on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for UBRELVY and any potential adverse effects on the breastfed infant from UBRELVY or from the underlying maternal condition.

Is it safe to use UBRELVY in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Are there any pharmacokinetic differences between elderly and younger patients when taking UBRELVY?

Pharmacokinetic studies have shown no clinically significant differences between elderly and younger patients when taking UBRELVY.

Was the use of UBRELVY studied in elderly patients?

Clinical studies of UBRELVY did not include enough elderly patients to determine if they respond differently from younger patients. Dose selection for elderly patients should be cautious and typically start at the low end of the dosing range.

How does hepatic impairment affect the exposure to UBRELVY?

In patients with mild, moderate, or severe hepatic impairment, exposure to UBRELVY was increased by 7%, 50%, and 115%, respectively. No dose adjustment is necessary for mild or moderate hepatic impairment. However, for patients with severe hepatic impairment, dose adjustment is recommended.

How does renal impairment affect the use of UBRELVY?

Renal impairment has a minor effect on the clearance of UBRELVY. No dose adjustment is needed for patients with mild or moderate renal impairment. For those with severe renal impairment (CLcr 15-29 mL/min), dose adjustment is necessary. Patients with end-stage renal disease (CLcr <15 mL/min) should avoid the use of UBRELVY.

Qulipta® Alternatives